ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density
Dahan A, Dunne A, Swartjes M, Proto PL, Heij L, Vogels O, van Velzen M, Sarton E, +4 more
Molecular Medicine (2013) · n=48
Twenty-eight days of daily subcutaneous cibinetide in sarcoidosis patients with documented small-nerve-fiber loss produced a significant increase in corneal small-nerve-fiber density, improved thermal sensitivity, and increased exercise capacity — the trial that anchored the move from a pilot signal to a structurally defensible Phase II readout.
This is the follow-up Phase II randomized double-blind placebo-controlled trial of ARA-290 (cibinetide) in sarcoidosis patients with documented small-nerve-fiber loss, published in Molecular Medicine in 2013 by Dahan and colleagues at Leiden University Medical Center in collaboration with Araim Pharmaceuticals. The trial built on the Heij et al. 2012 pilot by extending the patient population, lengthening the treatment course to 28 days of daily subcutaneous dosing, and incorporating tissue-level disease-modification endpoints alongside the patient-reported symptom score.
The reported endpoints span three distinct levels of evidence. At the patient-reported level, ARA-290 produced significant improvement in neuropathic symptoms versus placebo. At the tissue-level disease-modification layer, ARA-290 administration was associated with a statistically significant increase in corneal small nerve fiber density measured by corneal confocal microscopy — a defensible mechanism-resolved endpoint that captures intraepidermal small-fiber regeneration directly rather than via patient self-report. At the functional level, ARA-290 produced changes in cutaneous temperature sensitivity (cold pain threshold P=0.027; hot pain threshold P=0.032; thermal discrimination P=0.008) and an increase in six-minute walk distance — a generic exercise-capacity endpoint that has surprising face validity in small-fiber neuropathy populations where autonomic dysfunction limits exercise tolerance. The signal was preserved over a follow-up window extending beyond the 28-day treatment course.
The trial is the structural inflection point in the cibinetide development program: the move from a 22-patient pilot to a Phase II trial with mechanistically informative endpoints (corneal confocal microscopy, intraepidermal nerve fiber density, thermal-threshold psychophysics), enabling the subsequent Culver et al. 2017 Phase IIb dose-finding trial (64 patients across placebo and three cibinetide doses) that confirmed the corneal-nerve-fiber-density primary endpoint at the 4 mg/day dose. Together with the Brines et al. 2008 mechanism paper, the Heij 2012 pilot, the Brines 2015 diabetic-neuropathy trial, and the Culver 2017 Phase IIb, this is the second of four trials that constitute the published Phase II evidence base for ARA-290 across two distinct neuropathic conditions. The ARA-290 peptide page covers the broader development trajectory.
The 48-patient sample size remains modest by the standards of pivotal-grade clinical trials and adequate only for Phase II proof-of-concept rather than confirmatory inference. The trial was conducted at Leiden University Medical Center; the development program has not been replicated in non-affiliated centers at meaningful scale, and the multicenter Phase III trial that would address center-effect generalizability has not been conducted. The 28-day treatment duration is short relative to the chronic-disease framing of small-fiber neuropathy, and the extended follow-up does not characterize long-term safety or efficacy. The corneal-confocal-microscopy endpoint is methodologically defensible and has the advantage of being a tissue-level structural readout, but it is not yet a regulatory-grade primary endpoint in any indication and the cross-laboratory standardization required for multicenter pivotal use is still being built. Sponsorship by Araim Pharmaceuticals is disclosed; co-authors Cerami and Brines are Araim co-founders with substantial financial interests in the molecule's development; the investigator team at Leiden has been the central academic-clinical partner for the cibinetide program across all four published Phase II trials. The trial population was specifically selected for documented small-nerve-fiber loss (rather than broader neuropathic-symptom populations) and the efficacy signal applies most directly to that enriched population. Commercial development of the molecule stalled in the late 2010s after the Culver 2017 readout; no Phase III trial has been completed in any indication, and the apparent persistence of the gray-market use of cibinetide for indications outside the trial-evidence base is one of the broader /peptides/ara-290 caveats this entry sits beneath.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.